Abstract
ASTRIS is the largest global wide study of osimertinib in a real-world setting in patients with EGFR T790M mutation-positive advanced NSCLC. Here we present the final analysis of Chinese subset of the ASTRIS study.
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have